Table 1.
Baseline characteristics of the patients with COVID-19, laboratory and clinical findings at hospital admission.
| Sociodemographic and clinical data | Whole study group of patients with COVID-19 | Group 1 patients without post-COVID syndrome | Group 2 patients with post-COVID syndrome | p value (M-W test) gr.1 vs. gr.2 |
|---|---|---|---|---|
| Number of participants | 36 | 16 | 20 | |
| Age, years (median, range) | 56 (36–67) | 47 (36–65) | 57 (34–65) | 0.18 |
| Length of hospitalization, days (median, range) | 10 (0–25) | 9 (6–25) | 11 (0–25) | 0.98 |
| Symptoms, N (%) | ||||
| Dyspnea | 17 (61) | 9 (69) | 8 (53) | 0.49 |
| Fever | 22 (79) | 11 (85) | 11 (73) | 0.62 |
| Cough | 20 (71) | 9 (69) | 11 (73) | 0.86 |
| Sore throat | 3 (11) | 2 (15) | 1 (7) | 0.72 |
| Weakness | 21 (75) | 10 (77) | 11 (73) | 0.89 |
| Olfactory disorders | 4 (14) | 2 (15) | 2 (13) | 0.93 |
| Diarrhea | 3 (11) | 1 (8) | 2 (13) | 0.82 |
| Headache | 5 (18) | 2 (15) | 3 (20) | 0.85 |
| Comorbidities, N (%) | ||||
| Hypertension | 10 (28) | 3 (19) | 7 (35) | 0.56 |
| Cardiological diseases | 1 (3) | 0 (0) | 1 (5) | 0.86 |
| Vascular diseases | 2 (6) | 1 (6) | 1 (5) | 0.96 |
| Diabetes | 1 (3) | 0 (0) | 1 (5) | 0.86 |
| Obesity | 3 (8) | 2 (13) | 1 (5) | 0.76 |
| Endocrine diseases | 4 (11) | 2 (13) | 2 (10) | 0.93 |
| Rheumatological diseases | 4 (11) | 1 (6) | 3 (15) | 0.75 |
| Gastrointestinal diseases | 2 (6) | 1 (6) | 1 (5) | 0.96 |
| Renal diseases | 3 (8) | 1 (6) | 2 (10) | 0.90 |
| Laboratory examinations | ||||
| Leukocytes, µL− 1 (median, range) | 5.58 (3.02–17.31) | 4.75 (3.02–17.31) | 5.67 (3.62–8.84) | 0.75 |
| Platelets, x 1000 µL− 1 (median, range) | 198.50 (105–444) | 220 (105–444) | 192 (125–267) | 0.41 |
| C-reactive protein, mg/dl (median, range) | 12.83 (0.9-134.2) | 16.3 (0.9-134.2) | 10.145 (1.4-133.23) | 0.75 |
| Procalcitonin µg/L, (median, range) | 0.05 (0.02–0.5) | 0.05 (0.03–0.5) | 0.05 (0.02–0.2) | 0.78 |
| Ferritin µg/L, (median, range) | 257.3 (3.7–2838) | 208.7 (3,7-1242) | 642.15 (10,9-2838) | 0.15 |
| IL-6 pg/ml, (median, range) | 6,5 (1,5-196,8) | 5 (1,5-113,6) | 12,7 (1,5-196.8) | 0.49 |
| Antibodies anti-SARS-CoV-2 Trimer I, (median, range) | 360 (0-2080) | 514.5 (4.81–2080) | 170 (0-2080) | 0.60 |
| Antibodies anti-SARS-CoV-2 Trimer II, (median, range) | 1390 (0.87–2080) | 896 (188–2080) | 1410 (0.87–2080) | 0.43 |
| Imaging, N (%) | ||||
| CT typical changes (ground glass opacities and crazy-paving pattern) | 22 (61) | 9 (56) | 13 (65) | 0.69 |
| Treatment, N (%) | ||||
| Actemra/RoActemra (tocilizumab) | 2 (6) | 1 (10) | 1 (7) | 0.89 |
| Neoparin (endoxaparinum natricum) | 20 (56) | 8 (80) | 12 (80) | 1.0 |
| Remdesivir | 4 (11) | 1 (10) | 3 (20) | 0.68 |
| Dexamethasone (glucocorticosteroid) | 14 (39) | 8 (80) | 6 (40) | 0.10 |
| Budesonide (glucocorticosteroid) | 2 (6) | - | 2 (13) | - |
Abbreviations: COVID-19 - Coronavirus disease 19, N-number of patients, IL-6 – interleukin 6, CT- computed tomography scan.